{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:51:42Z","timestamp":1778226702934,"version":"3.51.4"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research and institute of National Cancer Center","award":["1710290-2"],"award-info":[{"award-number":["1710290-2"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211105","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T19:38:08Z","timestamp":1550691488000},"page":"e0211105","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy"],"prefix":"10.1371","volume":"14","author":[{"given":"Sung Han","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Kwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-5282","authenticated-orcid":true,"given":"Eun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungnam","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-5203","authenticated-orcid":true,"given":"Jinsoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"Suppl 2","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S2-01","article-title":"New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview","volume":"16","author":"RJ Motzer","year":"2011","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"g4797","DOI":"10.1136\/bmj.g4797","article-title":"Renal cell carcinoma","volume":"349","author":"E Jonasch","year":"2014","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2015.0022","article-title":"Kidney cancer, version 3.2015","volume":"13","author":"RJ Motzer","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ucl.2012.02.002","article-title":"Defining an individualized treatment strategy for metastatic renal cancer","volume":"39","author":"B Hu","year":"2012","journal-title":"Urol Clin North Am"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000342962","article-title":"New insights into the management of renal cell cancer","volume":"84","author":"N Pecuchet","year":"2013","journal-title":"Oncology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.juro.2017.03.076","article-title":"The Role of High Dose Interleukin-2 in the Era of Targeted Therapy","volume":"198","author":"J Gills","year":"2017","journal-title":"J Urol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2015.12.031","article-title":"Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis","volume":"70","author":"T Buchler","year":"2016","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ctrv.2013.09.003","article-title":"Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials","volume":"40","author":"R Iacovelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.03.004","article-title":"The molecular biology of renal cancer: another piece of the puzzle","volume":"66","author":"GD Stewart","year":"2014","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-013-0304-7","article-title":"Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer","volume":"9","author":"L Leon","year":"2014","journal-title":"Target Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4143\/crt.2015.316","article-title":"Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy","volume":"48","author":"SH Kim","year":"2016","journal-title":"Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"M Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"M Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"RR McKay","year":"2014","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.23776","article-title":"Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma","volume":"113","author":"RJ Motzer","year":"2008","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","article-title":"Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie","volume":"13","author":"S Negrier","year":"2002","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"TM Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.eururo.2013.07.031","article-title":"Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy","volume":"65","author":"N Kroeger","year":"2014","journal-title":"Eur Urol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1245\/ASO.2003.07.024","article-title":"Hepatic resection for metastatic renal tumors: is it worthwhile?","volume":"10","author":"A Alves","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7150\/jca.4456","article-title":"Liver directed therapy for renal cell carcinoma","volume":"3","author":"RC Langan","year":"2012","journal-title":"J Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/13651820500496266","article-title":"Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience","volume":"8","author":"TA Aloia","year":"2006","journal-title":"HPB (Oxford)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12072-015-9700-7","article-title":"Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review","volume":"10","author":"G Wang","year":"2016","journal-title":"Hepatol Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"74303","DOI":"10.18632\/oncotarget.11030","article-title":"Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma","volume":"7","author":"Y Ha","year":"2016","journal-title":"Oncotarget"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2008.01.027","article-title":"Racial\/ethnic and gender disparities in renal cell carcinoma incidence and survival","volume":"179","author":"HS Stafford","year":"2008","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40261-016-0428-5","article-title":"Sunitinib Possible Sex-Divergent Therapeutic Outcomes","volume":"36","author":"I Segarra","year":"2016","journal-title":"Clin Drug Investig"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"AA van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1245\/s10434-013-3290-1","article-title":"Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"20","author":"WA Kwon","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"LM Coussens","year":"2002","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semcancer.2013.02.005","article-title":"Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progression","volume":"23","author":"CA Dumitru","year":"2013","journal-title":"Semin Cancer Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T06:52:55Z","timestamp":1606546375000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211105"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211105","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]}}}